Fig. 6: Novel peptide-based elastase inhibitors suppress IL-36γ activation by proteases contained within human neutrophil degranulates.
From: Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases
a–c HeLaIL-36R-SEAP cells were either left untreated, or were treated with recombinant IL-36α, IL-36β, or IL-36γ (500 pM) that had been pre-incubated for 2 h at 37 °C with PMA-activated human neutrophil degranulate, in the presence or absence of a titration (10, 5, 2.5, 1, 0.5, or 0.25 μM) of the indicated candidate peptide inhibitors. After 24 h, cytokine concentrations in the culture supernatants were determined by ELISA. Results shown are representative of at least three independent experiments. Error bars represent the mean ±SEM of triplicate determinations from a representative experiment. Asterisk(s) indicate significance levels, ***p < .0001, **p < .001, *p < .1, by Student’s t test
